Literature DB >> 18030231

Celiac disease screening by immunochromatographic visual assays: results of a multicenter study.

Luis Carlos Blesa Baviera1, Ester Donat Aliaga, Luis Ortigosa, Néstor Litwin, Luis Peña-Quintana, Virginia Méndez, Ma Victoria González, Javier Manzanares López-Manzanares, Enrique Méndez, Carmen Ribes Koninckx.   

Abstract

OBJECTIVE: To assay the efficiency for celiac disease (CD) screening of 2 immunochromatographic visual stick assays based on human recombinant tissue transglutaminase (tTG). One was the antitissue transglutaminase antibodies (AtTGA) stick for IgA/G antibodies to tTG detection, the other was the AtTGA/antigliadin antibodies (AGA) stick for IgA antibodies for tTG and/or gliadins. PATIENTS AND METHODS: In a prospective multicenter study, 4 pediatric gastroenterology units from Spain and 2 from Latin America enrolled 72 control children with a normal small bowel mucosa and 113 untreated patients with CD with Marsh type 3 lesions.
RESULTS: Evaluation of results by the gastroenterologists and by 2 independent observers at the coordination center showed a remarkably low interobserver variability. For the AtTGA stick, sensitivity was 96.5% and specificity was 98.6%. The AtTGA/AGA stick displayed a sensitivity of 94.5% and a specificity of 98.6% for AtTGA and a sensitivity of 63.1% and a specificity of 95.2% for AGA. The highest efficiency and positive likelihood ratio was obtained for the AtTGA stick, higher than for IgA AtTGA by enzyme-linked immunosorbent assay. One additional advantage was that previous investigation of total serum IgA levels could be eluded. The IgA AtTGA/AGA stick, with an efficiency of 95.1%, compared with 89.2% when the combined results of the 2 enzyme-linked immunosorbent assays were considered, turned out to be an excellent diagnostic tool for infants with no IgA deficiency.
CONCLUSION: These 2 assays are extremely efficient for CD screening, by combining a high diagnostic accuracy with the simplicity and rapidity of visual methods.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18030231     DOI: 10.1097/MPG.0b013e31814794b9

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  6 in total

1.  One-step immunochromatographic visual assay for anti-transglutaminase detection in organ culture system: An easy and prompt method to simplify the in vitro diagnosis of celiac disease.

Authors:  Marco Di Tola; Mariacatia Marino; Rossella Casale; Raffaele Borghini; Antonio Tiberti; Giuseppe Donato; Umberto Occhiuzzi; Antonio Picarelli
Journal:  J Clin Lab Anal       Date:  2017-03-09       Impact factor: 2.352

2.  The Role of an IgA/IgG-Deamidated Gliadin Peptide Point-of-Care Test in Predicting Persistent Villous Atrophy in Patients With Celiac Disease on a Gluten-Free Diet.

Authors:  Michelle S Lau; Peter D Mooney; William L White; Michael A Rees; Simon H Wong; Matthew Kurien; Nick Trott; Daniel A Leffler; Marios Hadjivassiliou; David S Sanders
Journal:  Am J Gastroenterol       Date:  2017-10-10       Impact factor: 10.864

3.  A point-of-care test for facing the burden of undiagnosed celiac disease in the Mediterranean area: a pragmatic design study.

Authors:  Stefano Costa; Luca Astarita; Mongi Ben-Hariz; Giovanni Currò; Jernej Dolinsek; Aydan Kansu; Giuseppe Magazzu'; Stefania Marvaso; Dusanka Micetic-Turku; Salvatore Pellegrino; Giuseppe Primavera; Pasqualino Rossi; Andrea Smarrazzo; Francesca Tucci; Carmela Arcidiaco; Luigi Greco
Journal:  BMC Gastroenterol       Date:  2014-12-18       Impact factor: 3.067

Review 4.  The Gluten-Free Diet for Celiac Disease and Beyond.

Authors:  Bara Aljada; Ahmed Zohni; Wael El-Matary
Journal:  Nutrients       Date:  2021-11-09       Impact factor: 5.717

5.  Clinical utility of serologic testing for celiac disease in ontario: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2010-12-01

6.  Point-of-care testing for coeliac disease: primary care diagnostic technology update.

Authors:  Jaspreet Khangura; Ann Van den Bruel; Rafael Perera; Carl Heneghan; Christopher P Price; Jane Wolstenholme; Matthew Thompson; Annette Plüddemann
Journal:  Br J Gen Pract       Date:  2013-06       Impact factor: 5.386

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.